Skip to content

LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that LIDDS new CEO Nina Herne will hold her first presentation at Redeye’s Growth Day on June 2 at 13.50 pm CET.


To follow the event, please register here:      

Nina will also present at Aktiespararnas Småbolagsdagarna on June 8 at 13.30 pm CET.

The seminar can be followed live at:

 “I look forward to present LIDDS at both events and I am excited to talk about the growth of the company going forward. We are entering an exciting period with development in our pipeline, interesting collaborations and a planned and disclosed move up to the Nasdaq Stockholm main market," said Nina Herne, CEO.

 Nina Herne started as the CEO of LIDDS in April and this will be her first presentations since her appointment. There will be room for questions at both events.  


 For more information, please contact:

Nina Herne, CEO, Phone: +46 (0)70-714 74 57, Email:

 LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB,, +46 (0)8 121 576 90, is a certified adviser to LIDDS.  For more information, please visit